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Hydrogel-based scaffolds to support intrathecal stem cell
transplantation as a gateway to the spinal cord: clinical needs,
biomaterials, and imaging technologies
J. Miguel Oliveira 1,2,3, Luisa Carvalho1,2, Joana Silva-Correia1,2, Sílvia Vieira1,2, Malgorzata Majchrzak4, Barbara Lukomska4,
Luiza Stanaszek4, Paulina Strymecka4, Izabela Malysz-Cymborska5, Dominika Golubczyk5, Lukasz Kalkowski5, Rui L. Reis1,2,3,
Miroslaw Janowski4,6,7 and Piotr Walczak5,6,7
The prospects for cell replacement in spinal cord diseases are impeded by inefﬁcient stem cell delivery. The deep location of the
spinal cord and complex surgical access, as well as densely packed vital structures, question the feasibility of the widespread use of
multiple spinal cord punctures to inject stem cells. Disorders characterized by disseminated pathology are particularly appealing for
the distribution of cells globally throughout the spinal cord in a minimally invasive fashion. The intrathecal space, with access to a
relatively large surface area along the spinal cord, is an attractive route for global stem cell delivery, and, indeed, is highly
promising, but the success of this approach relies on the ability of cells (1) to survive in the cerebrospinal ﬂuid (CSF), (2) to adhere to
the spinal cord surface, and (3) to migrate, ultimately, into the parenchyma. Intrathecal infusion of cell suspension, however, has
been insufﬁcient and we postulate that embedding transplanted cells within hydrogel scaffolds will facilitate reaching these goals.
In this review, we focus on practical considerations that render the intrathecal approach clinically viable, and then discuss the
characteristics of various biomaterials that are suitable to serve as scaffolds. We also propose strategies to modulate the local
microenvironment with nanoparticle carriers to improve the functionality of cellular grafts. Finally, we provide an overview of
imaging modalities for in vivo monitoring and characterization of biomaterials and stem cells. This comprehensive review should
serve as a guide for those planning preclinical and clinical studies on intrathecal stem cell transplantation.
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INTRODUCTION
Central nervous system (CNS) diseases and injuries are some of
the most devastating for patients. The complexity and role of the
CNS is such that its functional deterioration results in a huge
impact on the quality of life, as well as an enormous ﬁnancial
burden to society. Cellular degeneration and death are the most
common features of CNS disorders. In that way, several
approaches that have attempted to regenerate cells, tissues, or
organs in order to restore or establish normal function have been
studied. In many instances, transplanted stem cell suspensions
were shown to be highly therapeutic in small-animal models,1 but
that was attributable to the broad distribution of transplanted
cells in the CNS.2 The attempt to translate these exciting results to
the clinical scenario has been challenging. While several clinical
trials report therapeutic beneﬁt,3,4 many other trials report good
safety proﬁle but no efﬁcacy,5–7 triggering the closing of some
cell-manufacturing companies. Such disappointing clinical transla-
tion results can be attributed to the large difference in the size of
the CNS between mice and humans, as the mouse brain is 1000
times smaller. The issue of cell distribution in the large CNS must
be addressed prior to the pursuit of more clinical research. Herein,
we discuss the current clinical needs and solutions that have been
used in cell-based therapies, with a particular focus on targeting
the spinal cord. Recent reports dealing with hydrogels and
nanoparticles for cell delivery to the CNS are also reviewed. The
modulation of the microenvironment of cell-laden hydrogels with
the use of nanoparticles and engineering strategies to allow
in vivo imaging are also discussed in depth.
TARGETING THE SPINAL CORD: CLINICAL NEEDS AND
SOLUTIONS
Intraventricular8 and intra-arterial9 routes are very promising for
the delivery of stem cells to the brain. However, efﬁcient delivery
of stem cells to the broad areas of the spinal cord needs still to
being resolved. There are several gateways to the spinal cord that
have been considered, including the central canal, the intra-
arterial, the intraparenchymal, and/or the intrathecal routes.
Schematic representation of the cell/biomaterial constructs
delivery routes into the spinal cord is depicted in Fig. 1.
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Central canal
The central canal of the spinal cord, an extension of the ventricular
system, is a relatively narrow space, which also plays a central role
in the CSF circulation. The obstruction of the cerebrospinal ﬂuid
(CSF) circulation following injection of stem cells could lead to a
very debilitating disorder, syringomyelia,10 and thus, this route of
cell delivery should be pursued clinically only after extensive
research on large animals (Fig. 1a).
Intra-arterial
Blood for the spinal cord is supplied by a number of small
segmental arteries, which are difﬁcult to reach with an endovas-
cular catheter, and, importantly, the obstruction of these arteries
can result in serious and disabling consequences.11 Considering
that most of the potential targets for therapy are within the
cervical spine, any vascular occlusion or injury in this area may
result in severe neurological deﬁcits that could affect most of the
body, including tetraplegia. In this context, the intra-arterial route
for cell delivery to the spinal cord should be considered with
extreme caution (Fig. 1b).
Intraparenchymal
Direct needle injections, including multi-site injections, are
currently the most actively pursued strategy with which to deliver
stem cells to the spinal cord, as it has been shown to be effective
in small animals.12 While the procedure has been shown to be safe
in large animals13,14 and open-label phase I/II clinical trials,15,16 the
puncture of the spinal cord is a very complex and expensive
procedure. Intraparenchymal delivery is also not well suited for
disorders with global or multifocal pathology, as each injection
delivers cells to only a relatively small volume of tissue. Multiple
injections might be considered to improve cell biodistribution;
however, that ampliﬁes the risk of damage and any potential
therapeutic effects could be offset by the procedure-related
morbidity. The need for neurosurgical virtuosity and specialized
injectors might limit the widespread application of this route. The
invasive nature of intraparenchymal injection requires the ability
to gain surgical access to the spinal cord, including muscle
dissections and multilevel laminectomies. In addition, repeated
needle insertion increases the risk for injury of a parenchymal
vessel, with the resultant neurological consequences. Therefore,
this approach is another example where direct translation of
Fig. 1 Injection routes of stem cell/biomaterial constructs into the spinal cord
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therapeutic effectiveness from small animals to patients may be
challenging (Fig. 1c).
The spinal cord is thus a difﬁcult target in which to achieve
effective, global delivery of stem cells and there is a clear clinical
need for a robust, minimally invasive, and safe method for
efﬁcient and repeatable stem cell delivery to the spinal cord. The
low volume-to-surface ratio (in contrast to the brain) and easy
access speaks in favor of using the extraspinal space as a route of
cell delivery.
Intrathecal
The extraspinal space is ﬁlled with a CSF, and, most importantly,
can be easily approached through a lumbar puncture, a method
routinely used to sample the CSF, for drug delivery, as well as to
lower CSF pressure during neurosurgical procedures. The use of
widely available ﬂuoroscopic guidance allows placement of a
catheter tip at the desired position, such as the cervical area.17
Thus, if this route were effective, it could immediately be applied
worldwide; however, several challenges need to be addressed
before this approach can become a clinical reality. The most
important is that the cells deployed to the CSF need to traverse
the pia matter and enter the parenchyma of the spinal cord in the
desired region. There is strong evidence about ability of the cells
to migrate from the CSF compartments into parenchyma on early
stage of development;2 however, adult or aging pia matter will
likely be more challenging barrier to traverse. Some potential
solutions to this challenge could be engineering the cells for
expression of metalloproteinases18 or supplementation of bioma-
terials with enzymes selectively targeting collagen and reticular
ﬁbers of pia. The second challenge is that the cells injected as a
suspension (Fig. 1d) settle due to gravity, and, in humans, usually
accumulate below the spinal cord around the cauda equina
(Fig. 1d’). Potentially, both challenges, i.e., adhesion to the spinal
surface and sedimentation can be addressed by embedding cells
within the hydrogel-based scaffold (Fig. 1e,e’,e”). This, in turn, calls
for providing an appropriate environment that would match the
requirements of the cell type and could be addressed by the use
of nanoparticles that could slowly release the desired trophic
factors. In subsequent sections, we will extensively review the
options for the biomaterials (hydrogels and nanoparticles) to
address the unmet need for stem cell delivery to the spinal cord
via the intrathecal space.
HYDROGELS AS SCAFFOLDS FOR STEM CELL DELIVERY
The application of appropriate scaffolding biomaterial matrices
has gained a new impetus to repair the CNS because of the huge
developments in cell engineering and cell-based treatment
solutions. Scaffolds, by including natural extracellular matrix
(ECM) proteins, can direct cell behavior by providing cues about
cells during migration, differentiation, and regeneration in the CNS
environment.19 In particular, the use of hydrogel systems is an
attractive approach for stem cell delivery, as these systems can
serve as temporary mimetic niche with which to support the
survival of transplanted cells or recruited endogenous cells at the
lesion site to promote recovery.20 The high-water content and
tissue-like mechanical properties of hydrogels make them highly
attractive scaffolds for implantation in soft tissue.21 Furthermore,
the hydrogels present porous structures that allow cell attachment
and growth, as well as the “smart” release of biological agents at
the injury site.21,22
With respect to application in the spinal cord, hydrogels are the
system of choice to provide the appropriate mechanics for precise
localization and spatio-temporal control of cell delivery, and that is
particularly important in case of transplantation to the intrathecal
space. The rationale for using injectable hydrogels for intrathecal
stem cell delivery is based on the observations that stem cells
transplanted into the CSF are subject to gravitational sedimenta-
tion.8 In addition, cells injected into the CSF may lack cell–cell
contact and RGD signaling. Indeed, it has been shown that RGD
signaling provided as part of the biomaterial system improves cell
survival and function.23 The quality of hydrogels that is critical,
with respect to their use in highly sensitive tissues of the CNS, is
that they are biocompatible, minimizing adverse tissue reaction
in vivo.24 Hydrogels can be easily tuned (composition and
functionalization) in order to facilitate injectability. Their biome-
chanical properties can be adjusted for smooth ﬂow with low
resistance during infusion, as well as to broadly mimic the host
microenvironment composition, including physical and mechan-
ical characteristics representative of native CNS tissue, which
minimizes mechanical mismatch.25
Both physical and covalently cross-linked hydrogels have been
applied to the treatment of spinal cord injury (SCI). Until now, only
a few studies reported the development of injectable hydrogel
systems for the intrathecal delivery of cells to the CSF. Physical
gels are simpler to use, since they typically do not involve harsh
cross-linking conditions, thus reducing the possible toxicity
normally associated with the use of covalent coupling agents.26
In fact, these types of gels often require a gelation-triggering
system, such as local cooling,22 which introduces the risk of tissue
damage, and, in case of intrathecal injection, is not applicable.
Chemically cross-linked hydrogels, however, are relevant
because they present more desirable properties than physical
gels in terms of ﬂexibility to manipulate physical and biological
properties. Synthetic functional groups can be incorporated in the
polymers to enable (or enhance) gelation, for improved in vivo
stability, or to enhance speciﬁc enzymatic susceptibility of the
hydrogels.27 Chemically cross-linked hyaluronan is an example
where researchers exploited the biocompatible, biodegradable,
angiogenic, and anti-inﬂammatory nature of the base polymer. For
example, Gupta et al.28 described, for the ﬁrst time, the physical
blend of an HA and methyl cellulose (HAMC)-injectable hydrogel
to deliver NSCs into the rat brain after a clip compression injury.
Also, Mothe et al.29 examined the survival and efﬁcacy of adult
brain-derived neural stem/progenitor cells (NSPCs) injected within
a modiﬁed HAMC hydrogel with recombinant rat platelet-derived
growth factor-A (rPDGF-A). The authors showed that, while only a
limited number of surviving cells was found, the hydrogel
promoted the survival of host neurons and oligodendrocytes,
which was associated with better functional recovery on the
ladder walk.29 Further, the same authors reported that the
modiﬁcation of the previously used HAMC with RGD promoted
the survival, integration, and differentiation of human pluripotent
stem cell-derived oligodendrocyte progenitor cells30 (Fig. 2). While
over-proliferation of the cells was reported in that study, it
demonstrated that the modiﬁed HAMC hydrogel reduces tumor
formation by promoting differentiation in vivo. Control animals
that received cells without hydrogel demonstrated extensive
tumor formation and a decline in motor function.31 A combination
of peptide-modiﬁed gellan gum (GG-GRGDS) hydrogels also
showed a great potential to be used in cellular therapies designed
to treat SCI. A co-culture of adipose stem cells (ASCs) and olfactory
ensheathing cells (OECs) encapsulated into the GG-GRGDS
hydrogel resulted in signiﬁcant motor and histological improve-
ments of SCI in rats.32
In brief, the selection of biomaterials, the surface morphology of
the substrates, neurotrophic factors, cell density, and the effect of
serum and many other factors can all affect the proliferation and
differentiation of cultured neural stem cells. When envisioning the
design of the cell culture environment in vitro and in vivo, as
many factors as possible related to biomaterials should be
considered and optimized to achieve the best biological
performance, in the short-term, medium-term, and long-term. All
these studies provide a promising strategy, combining a
biocompatible and injectable polymer and stem cells to form an
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effective cell transplantation system for the treatment of spinal
cord diseases. In order to develop more efﬁcient treatment
solutions, future research should focus on optimizing the
conditions for augmenting stem cell survival, proliferation,
migration, differentiation, and integration into the host tissue.
NANOPARTICLES FOR THE MODULATION OF THE
MICROENVIRONMENT OF CELL-LADEN HYDROGELS
One of the most important characteristics of hydrogels that
determine local microenvironment and injectability are their
rheological properties33 and it has been shown that the
rheological properties of a given hydrogel vary.34 When a
hydrogel is injected, its rheological behavior and viscoelastic
properties (storage modulus and loss modulus, G’ and G”,
respectively) are negatively affected. In order to improve the
viscoelastic properties, without altering the gel-like behavior of
both acellular and cell-laden hydrogels, nanoparticles have been
used as a reinforcement or ﬁller material.33,35
In fact, the use of nanoparticle-based systems has expanded
interest because of the exciting prospects.36 The use of materials
at the nanoscale provides the extraordinary possibility to modify
some of the properties of therapeutic carriers, such as solubility,
diffusivity, biodistribution, release characteristics, and immuno-
genicity. In addition, these kinds of carriers show a longer
circulation half-life, superior bioavailability, and lower toxicity.37,38
Despite the large number of nanocarriers that are being
developed and investigated for speciﬁc drug delivery purposes
in the CNS, only a few studies have reported its application in the
CSF. The vast majority of NPs for the CNS range from classical
linear polymers to novel spherical molecules. For example,
dendrimers that have a spherical morphology and highly
branched have been shown to be interesting nanocarriers for
CNS applications. They facilitate surface functionalization and
control over their size, which inﬂuences the drug payload and
targeting features.39,40 There are different dendrimers that have
been exploited extensively for drug delivery, including poly
(amidoamine) (PAMAM), poly(etherhydroxylamine) (PEHAM), and
poly(propyleneimine) (PPI) dendrimers.41 Because of their unique
structures and properties, PAMAM dendrimers have been the
most investigated for the use in CNS applications. In fact, Oliveira
et al. reported a new functionalization for a PAMAM dendrimer, by
grafting it to a carboxymethylchitosan (CMCht) to improve the
loading capacity.42 That nanocarriers were shown to be inter-
nalized by primary neurons and glial cells in culture system,
suggesting their utility for CNS indications39 (Fig. 3). In another
study, the corticosteroid, methylprednisolone (MP), was incorpo-
rated into the CMCht/PAMAM and administered directly into the
CSF in the cisterna magna of Wistar rats. This study showed that
MP-loaded CMCht/PAMAM broadly diffused in the healthy rat
brain following administration in the CSF, while delivering MP. The
incorporation of MP into a dendrimer formulation was responsible
for modulation of the metabolic activity of microglia.43 Recently, a
few studies have reported on another approach using magnetic
nanoparticles (MNPs) for magnetic guidance of drugs and their
targeted delivery.44,45 Lueshen et al.46 developed a physiologically
and anatomically consistent in vitro human spine model that
reproduced natural CSF pulsations to infused gold-coated
magnetite nanoparticles. This system allowed a more targeted
drug delivery to speciﬁc regions using an external magnetic ﬁeld.
The same authors proved the increase in targeting efﬁcacy using
magnetizable implants.47 More recently, they validated this
intrathecal magnetic drug targeting (IT-MDT) approach in vivo
using Sprague-Dawley rats.48
With regard to the linear polymers, one of the most widely used
for drug delivery is poly(d,l-lactic-co-glycolic acid) (PLGA), since it
is biodegradable and there is minimal systemic toxicity associated
with CNS applications.49 Minocycline-loaded PLGA nanoparticles
showed no in vitro degradation of the drug in artiﬁcial CSF during
the seven-day stability study.50
In addition to the use of nanoparticles for drug or growth factor
delivery systems, nanoparticles have gained special attention for
stem cell tracking, namely, MNPs for detection by MRI. Cell
tracking is important, as it allows for a better understanding and
optimization of cell-mediated effects.51 Meta-analyses of cell-
mediated effects in preclinical cell therapy studies in neurological
disorders have revealed the primary therapeutic mechanisms52
and nanotechnology can offer a non-invasive monitoring system
for further improving these positive effects.
Fig. 3 Internalization experiments within cortical glial cell cultures.
a Astrocytes were able to internalize the FITC-labeled CMCht/
PAMAM dendrimer nanoparticles after 48 h of incubation. b
Oligodendrocytes also were able to internalize the FITC-labeled
CMCht/PAMAM dendrimer nanoparticles. Representative image of
the nanoparticles distributed along the intracellular compartment.
Adapted from Salgado et al.39
Fig. 2 Effect of immobilization of GRGDS peptide on HAMC hydrogels for the differentiation of rat NSPCs. Confocal images of rat NSPCs after
encapsulation in 0.5/0.5 wt% HAMC gels for 7 days. Cells were stained for anti-RIP (for oligodendrocytes, red) and counterstained with DAPI
(for cell nuclei, blue). Reprinted from Tam et al.30
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NON-INVASIVE IMAGING OF INTRATHECALLY INJECTED
BIOMATERIALS
The advantages of injecting cells via intrathecal route are clear as
discussed above. The challenge, however, is related to the
uncertainty about cell biodistribution and potentially high
variability of biomaterial/cell dispersal. While direct intraparench-
ymal injection results in highly reproducible and rather predict-
able placement,53 in case of injection into the ﬂuid compartments
uncertainty is high. This uncertainty is related to the mixing and
dilution of biomaterial with CSF and its redistribution with ﬂuid
circulation. In this context, it is highly desirable to monitor injected
biomaterials using non-invasive imaging. Even though literature
on image-guided intrathecal injection of biomaterial/cell compo-
sites is very limited, application of this approach in other organ
systems is quite abundant thus here we will focus on the rationale
and the needs of imaging for intrathecal injection, and, will
suggest imaging strategies that are best suited to fulﬁll these
needs. There are three areas where imaging could assist in
improving the success of intrathecal biomaterial/cell injection
including monitoring the procedure of biomaterial injection in
real-time, longitudinal assessment and ﬁnally, molecular imaging
of the local microenvironment at the injection site (Fig. 4).
Imaging is expected to provide a breadth of information about
the biomaterial itself, the embedded cells, and the graft-tissue
interactions in the context of the healing process. Moreover, it is
important that imaging requirements, such as incorporation of the
contrast agent, does not alter the properties of the biomaterial,
does not interfere with biology of embedded cells, and, ideally,
does not compromise functional assessment by any imaging
modalities.54 The selection of the optimal imaging technique for a
particular application is not a trivial task, and multiple factors have
to be considered. One example is the case of a superﬁcial injection
within a few millimeters under the skin, in which a low-energy
imaging method (e.g., photoacoustic, ﬂuorescent or biolumines-
cent) is sufﬁcient to track hydrogel integrity and release of
therapeutics within the injected organism.55,56 However, to
monitor delivery into deep structures, such as intravascular or
intra-organ injection, including the intrathecal space, tomographic
techniques (e.g., MRI, PET, and X-ray) are usually required.57–59
Each imaging modality has unique properties with advantages
and disadvantages; here, we will review these features as they
relate to placement of biomaterials in the intrathecal space.
Interventional imaging of the injection procedure
Placement of the intrathecal catheter at the desired level of the
spinal cord is performed under ﬂuoroscopic visualization and this
procedure is routinely performed clinically with an example of
baclofen pump implantation for treatment of dystonia.60 Infusion
of drugs as ﬂuid suspension can be performed without complica-
tions even chronically over weeks or months, as they simply mix
with the CSF. Implantation of hydrogels, however, is more
demanding and requires more careful approach as it is desired
that the material would persist locally in a speciﬁc and selected
area of the intrathecal space over the required period of time.
When biomaterial is being injected, dynamic imaging can be used
to assure the precision of targeting and to minimize the risk of
excessive injection or misplacement. Indeed, misplacement of the
biomaterial may have negative consequences beyond the
suboptimal therapeutic effect, as misinjected graft could lead to
unwanted adverse effects. Infusion into intrathecal space results in
its rostral or caudal spread from the catheter tip, or combination of
the two. Without imaging in real-time, proper placement is
practically impossible. Monitoring biomaterial biodistribution can
be accomplished with the use of X-ray. X-ray imaging based on
phase contrast proved to be capable of detecting the hydrogel
structure without the addition of contrast agent. The nonporous
and porous PEG hydrogels were discernible from surrounding
water or soft tissue in vitro without the use of contrast agents.61 In
addition, Faraj et al.62 demonstrated that high-resolution com-
puted tomography (micro-CT) enables the determination of the
structure of soft scaffolds in vitro. In addition to low X-ray
attenuation of collagen-based hydrogels, different combinations
of contrast agents were used. It was shown that the application of
osmium tetroxide and uranyl acetate, or a combination of uranyl
acetate and lead citrate, allowed high-resolution 3D imaging of
the structure of the scaffolds. Lei et al.63 showed the possibility of
non-invasive tracking of radiopaque thermo-reversible hydrogels
after implantation, and the opportunity to obtain detailed 3D
morphological information in a real-time manner. Due to its
accessibility and low cost, X-ray imaging techniques are promising
tools for hydrogel observation but ionizing radiation is a concern
and the motivation for developing other imaging modalities such
as MRI. Indeed MRI is extensively used in biomedicine2,64 and
recently signiﬁcant progress has been made in interventional MRI
including real-time assessment of injected cells65 and biomater-
ials.66 MRI has many features that make it one of the most
Fig. 4 Non-invasive imaging of intrathecally injected cell/biomaterial constructs
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desirable and preferable imaging modalities for imaging in
biomedicine. These features include excellent soft tissue contrast,
tomographic capabilities, excellent anatomical information, and it
is non-invasive and radiation-free. MRI has been widely used for
in vivo and ex vivo analysis of biomaterials and transplanted cells,
and, while detection of native components of hydrogel has been
demonstrated,67 labeling with MRI contrast agent is usually
required. Imaging moiety is often introduced in the form of a
nanoparticle such as iron oxide68 gadolinium69,70 or ﬂuorine
nanoemulsions.71 Various types of nanocarriers have been
developed including more advanced systems with both ther-
apeutic and diagnostic components (Theranostic agents). Good
example of such theranostic agents in the contex of regenerative
medicine are iron oxide-based particles loaded with microRNAs
for simultaneous tracking and manipulation of transplanted
cells.72 Another application of nanoparticles for imaging is by
combining contrast mechanism for more than one modality
known as multimodality nanoparticles, such as a combination of
PET, near-infrared ﬂuorescence, and MRI73 While there are no
published reports on intrathecal injection of biomaterials guided
by dynamic imaging we would like to review several relevant
applications based on imaging of labeled stem cells.
Superparamagnetic iron oxide nanoparticles (SPION) are of
particular interest for stem cell tracking, since they, in general, do
not result in adverse effects on cell survival and functionality in
terms of differentiation capacity, gene expression proﬁles, or
migratory capacity.8,74 Bigini et al.75 labeled human fetal cells with
SPIO nanoparticles in the brain of mice with motor neuron
disease. It was reported that transplanted cells rapidly diffused
throughout the fourth ventricle at the level of the spinal cord, and
the labeling did not affect the proliferation and metabolic activity
of cells.75 MRI has been successfully used for the dynamic
assessment of cell biodistribution in real-time during intra-arterial
injection in rodents76 where imaging was instrumental in
optimizing the procedure of cell delivery. Recently, real-time MRI
monitoring has been applied to predict and improve the precision
of cell delivery into the brain in small-animal and large-animal
models.2 While real-time assessment of intrathecal injection of the
biomaterial with MRI has not been reported it is highly feasible
and application of this technique would likely provide important
clues on how to assure reproducibility, reliability and efﬁcacy of
intrathecal biomaterial/cell delivery.
Longitudinal imaging
While most of the requirements for imaging of biomaterials over
time are common with described above real-time imaging, there
are few unique challenges related to speciﬁcity. The advantage of
interventional imaging is an access to pre-injection baseline and
unequivocal interpretation of post injection images following
simple subtraction process. Longitudinal imaging introduces
uncertainty as some pathological processes may imitate signal
features of the graft with an example of hypointense signal
produced by both iron oxide nanoparticle-based contrast agents
and a hemorrhage.77 Nevertheless both X-ray and MRI has been
used for monitoring injected biomaterials over time. One example
is a study by Appel et al.78 showing that X-ray phase contrast (XPC)
CT application allows 3D visualization and quantiﬁcation of
hydrated soft tissues and PEG hydrogels in vivo, with no contrast
agents. The XPC CT imaging enabled a clear distinction between
surrounding tissue after transplantation and the hydrogel
structure. Also, tantalum, known for its biological properties of
facilitating soft tissue regeneration and vascularization, is, at the
same time a promising contrast agent for X-ray imaging,
enhancing the visibility of cells and biomaterial grafts.79 MRI has
been shown instrumental in the assessment of biomaterials
biodegradability in a study reported by Yang et al..80 That work
showed that the biodegradability level of hydrogels can be
monitored and quantiﬁed in vivo using an alteration of 19F
intensity. Recently, MR imaging of hydrogels transplanted as
scaffolds, as well as an injectable formulation, has been
reported.81 Zhang et al.82 presented in situ, cross-linkable, HA-
based hydrogels, hybridized with iron oxide nanoparticles to
enable their detection on MRI. Another interesting study used iron
oxide as a contrast agent and multiple crystals of iron oxide were
encapsulated inside the polyacrylamide matrix, yielding very high
relaxivity. Because of the monitoring of the amount of liberated
iron oxide nanoparticles by the hyaluronidases, it was possible to
monitor and analyze the hydrogel degradation.83 Bible and co-
workers84 showed non-invasive imaging of the ECM scaffold in a
stroke-damaged rat brain using 19F MRI, demonstrating that
transplantation of neural stem cells embedded in xenogeneic ECM
scaffolds resulted in uniformly distributed cells throughout the
lesion cavity.
Molecular and cellular imaging of the local microenvironment
One of the most challenging but highly rewarding tasks is non-
invasive imaging of the local microenvironment reporting on the
molecular processes within and around the injected biomaterial.
Greatest potential in that area has recently developed molecular
MRI technique that is based on chemical exchange saturation
transfer (CEST-MRI), which is a novel molecular MRI technique with
the important advantage that components which naturally occur
in the biomaterials are used to generate contrast.85 Endogenous
molecules dependent on the content of labile protons in the
sample may generate CEST contrast, thus facilitating their
detection by CEST-MRI without any additional contrast agent.
Liang et al.67 reported on the use of CEST-MRI to monitor
biodegradation of a gelatin-containing HA-based hydrogels, both
in vitro as well as in vivo in mice. In addition, Jin et al.86 described
the use of CEST for both in vitro and in vivo examination of ECM
hydrogels in a rat stroke model. In vitro CEST imaging was
instrumental in demonstrating dynamic changes in the different
components of the ECM inside the hydrogel. Moreover, in vivo
CEST examination allowed detection of ECM hydrogel distribution
and degradation that strongly corresponded to histological
studies post mortem.86 Chan et al.57 described pH nanosensor-
based magnetic resonance imaging as a modality with which to
image encapsulated cell death in vivo. Ultrapure, low-viscosity,
high-guluronate alginate and ultrapure, low-viscosity, high-
mannuronate alginate (NovaMatrix), and liposomes containing L-
arginine, were used for microcapsule preparation (Fig. 4). It was
shown that LipoCEST nanosensors were sensitive enough to
detect cell death caused by incomplete immunoprotection.
In the context of monitoring local cellular microenvironment it
is important to mention bioluminescence imaging (BLI). This
technique is based on a reporter gene (e.g., ﬁreﬂy luciferase) that
is expressed by the cells of interest. As the photon signal is
generated only by metabolically active cells and is dependent on
access to ATP, it is an excellent method for in vivo monitoring of
cell viability. Even though this modality is only applicable to small-
animal models it is invaluable for assessment of biomaterial/cell
composites. As described by Allen et al.87 GFP/Luc hMSCs were
embedded in (low-molecular-weight-irradiated RGD-functiona-
lized) alginate or in (SeaPlaque) agarose hydrogels and injected
subcutaneously in rats. Although both hydrogel types showed a
linear correlation between the BLI signal and the live cell number
using a 30-min imaging protocol, there was a difference in the
magnitude of the BLI signal measured between the agarose and
alginate materials, exemplifying the utility of BLI for monitoring
interactions between biomaterials and embedded cells. In
addition, Liang et al. showed that BLI is useful for monitoring
the viability of cells embedded in injectable hydrogel.88 That study
showed that HA-based hydrogels improved the survival and
proliferation of three different transplanted cell lines (C17.2 neural
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stem cells, ReNcells, and glial progenitors). Similarly, Levit et al.
used Luc hMSCs encapsulated in a low-viscosity guluronic acid-
based alginate (LVG, Novamatrix) in a rat myocardial infarction
model.89 BLI showed that encapsulation of MSCs in an LVG
hydrogel minimized scar formation and improved cardiac func-
tion. Similarly, luciferase-expressing ASCs (Luc ASCs) embedded
within ﬁbrin scaffolds and transplanted in the injured heart were
tracked with BLI as reported by Yang et al.90
Overall, several imaging modalities offer unique opportunities
for non-invasive monitoring of the intrathecal injection. Each of
the modalities has strengths and limitations with multimodality
approach likely required for providing most comprehensive
information.
CONCLUDING REMARKS AND FUTURE TRENDS
The spinal cord is clearly one of the most difﬁcult targets for the
transplantation of stem cells and one of the most challenging
elements is the route of cell delivery. Diseases characterized by
disseminated pathology require global cell engraftment, and, in
these cases, intrathecal injection seems to be highly recom-
mended. The infusion of cell suspensions directly into the CSF can
result in cell sedimentation and suboptimal cell biodistribution,
and hence, the need for supporting biomaterials. The transplanta-
tion of cells embedded in injectable hydrogels addresses the
problem of possible cell sedimentation while mimicking the native
extracellular matrix, additional beneﬁts of hydrogels include
bioadhesiveness and offer the potential for supplementation with
nanocarriers laden with molecules that can promote survival and
differentiation of stem cells. Finally, imaging technology offers
unique opportunities for the characterization of cell-biomaterial
composites both in vitro and after transplantation.
As shown above, there have been several reports that advocate
the use of the intrathecal route for stem cell delivery, and progress
in the ﬁeld of biomaterials is unprecedented, offering a breadth of
injectable hydrogel materials that meet the requirements of
intrathecal injection. While the applications for hydrogel-
embedded stem cells for intrathecal transplantation are limited,
we certainly hope this review will spark more interest in this
exciting area. Recent progress in the non-invasive imaging of
biomaterials, and, particularly, clinically applicable modalities, such
as MRI, will help guide the development of more effective and
safer protocols for intrathecal therapeutic cell transplantation.
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